Clinical Trial Update: Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies [Phase 3]

View source ↗

Summary

Phase 3 clinical trial updating the efficacy of benralizumab in patients with inadequate response to anti-IL5 therapies for severe prednisone-dependent eosinoph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prednisone-dependent Eosinophilic Asthma

Drugs mentioned

• Benralizumab (benralizumab)

Snippet

Sponsor: McMaster University | Conditions: Severe Prednisone Dependent Eosinophilic Asthma | Phase 3 | Status: COMPLETED